Telethon accesses RetroNectin from Takara to support gene therapies

Fondazione Telethon has tied up with Takara Bio for supply of RetroNectin to produce and distribute gene therapies.

Shreeyashi Ojha, Reporter

October 12, 2023

1 Min Read
Telethon accesses RetroNectin from Takara to support gene therapies
DepositPhotos/ depositedhar

Takara Bio will supply its proprietary RetroNectin method to Fondazione Telethon for use in the production of gene therapies, including Strimvelis. 

The agreement allows the Italian non-profit firm, Telethon, to use RetroNectin for commercial purposes including manufacturing products for cell and gene therapies (CGTs). Financial details have not been divulged. 


DepositPhotos/ depositedhar

A recombinant human fibronectin fragment, RetroNectin is a reagent that promotes colocalization of lentivirus or retrovirus with target cells to effectively enhance transduction. The RetroNectin approach is one of the most widely used standard protocols in engineering genes, T-cell based receptor (TCR), and chimeric antigen receptor (CAR) based therapies. Used in over 40 clinical trials, the method is a benchmark transduction enhancer for retroviral/lentiviral gene transfer to hematopoietic cells.  

Telethon will incorporate the reagent in the production of Strimvelis, an approved autologous cell therapy treatment for Adenosine deaminase deficiency, the rights of which Telethon added last month in a deal with Orchard Therapeutics. (Orchard, meanwhile, is set to be acquired by Japan-based pharmaceutical firm Kyowa Kirin.) 

The drug will be made available through San Raffaele Hospital in Milan from where it originated. Initially approved for reimbursement in 2016 by Agenzia Italiana del Farmaco (AIFA), the drug has been administered to a total of 45 patients across 20 countries. 

Neither Telethon nor Takara responded when contacted by this publication for further information.

About the Author(s)

Shreeyashi Ojha

Reporter, BioProcess Insider

Journalist covering the manufacturing and processing sectors for biopharmaceuticals globally.  

Originally from India, I am a Londoner at heart. I have recently graduated from Goldsmiths, University of London.  

Feel free to reach out to me at: [email protected].

You May Also Like